tldrdailynews.com logo

Merck's ADC Achieves 100% Response in Lymphoma Trials

1 min read
Source: Fierce Biotech
Merck's ADC Achieves 100% Response in Lymphoma Trials
Photo: Fierce Biotech
TL;DR

Merck & Co. has reported promising phase 2 trial results for its ROR1-directed antibody-drug conjugate (ADC), zilovertamab vedotin, showing a 100% complete response rate in patients with diffuse large B-cell lymphoma (DLBCL) at certain doses. Despite some safety concerns at higher doses, the company plans to advance the low dose into a phase 3 trial, comparing it to the standard R-CHOP regimen. The trial will focus on progression-free survival as the primary endpoint, with complete response and overall survival as secondary endpoints.

Topics:businesshealth#adc#cancer-treatment#clinical-trials#dlbcl#health#merck
Share this article
  1. Merck ADC RORs into phase 3 with 100% complete response rate  Fierce Biotech
  2. Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL  OncLive
  3. ASH: MSD’s ROR1 drug hits the target in first-line lymphoma  pharmaphorum
  4. Merck’s investigational ADC with R-CHP demonstrates 100% response rate for B-cell lymphoma  Indian Pharma Post
  5. Merck: encouraging results in diffuse lymphoma  Marketscreener.com

Want the full story? Read the original reporting

Read on Fierce Biotech